Genital herpes

disease
On this page

Also known as herpes genitaliaherpes genitalis

Summary

Genital herpes (MONDO:0005770) is a disease and 48 clinical trials. Top therapeutic interventions include valacyclovir, acyclovir, and famciclovir. A subtype of herpes simplex infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 48

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namegenital herpes
Mondo IDMONDO:0005770
EFOEFO:0007282
MeSHD006558
DOIDDOID:8704
NCITC14364
SNOMED CT33839006
UMLSC0019342
MedGen42436
Anatomy (UBERON)UBERON:0000990
Is cancer (heuristic)no

Also known as: herpes genitalia · herpes genitalis

Disease family

This is a subtype of herpes simplex infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious diseaseviral infectious disease › primary viral infectious disease › Herpesviridae infectious diseaseherpes simplex infectious diseasegenital herpes

Related subtypes (9): herpetic whitlow, herpes simplex dermatitis, herpes simplex virus gingivostomatitis, herpes simplex encephalitis, herpes simplex virus keratitis, congenital herpes simplex virus infection, herpes labialis, herpes simplex type 1 infectious disease, herpes simplex type 2 infectious disease

Subtypes (2): genital herpes simplex type 2 infectious disorder, genital herpes simplex type 1 infectious disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

3 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
AcyclovirApproved (phase 4)
FamciclovirApproved (phase 4)
ValacyclovirApproved (phase 4)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Amenamevir, Pritelivir, Sodium Chloride.

Clinical trials & evidence

Clinical trials

Clinical trials: 48.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified13
PHASE212
PHASE410
PHASE38
PHASE14
PHASE1/PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00079911PHASE4TERMINATEDA Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons
NCT00129818PHASE4COMPLETEDA Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
NCT00158860PHASE4COMPLETEDA Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
NCT00362297PHASE4COMPLETEDRandomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
NCT00477334PHASE4COMPLETEDPatient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients
NCT00495716PHASE4TERMINATEDEffect of HSV-2 Suppressive Therapy on Sexual Behavior
NCT00527618PHASE4COMPLETEDTrial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV
NCT00723229PHASE4COMPLETEDA Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation
NCT01346475PHASE4COMPLETEDRandomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
NCT03831165PHASE4COMPLETEDMelatonin Effects on Genital Herpes in Brazilian Women
NCT00005663PHASE3UNKNOWNA Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients
NCT00076232PHASE3COMPLETEDA Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
NCT00122525PHASE3TERMINATEDEffect of Male Circumcision on HIV Incidence (ANRS 1265)
NCT00124878PHASE3UNKNOWNTrial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community
NCT00171990PHASE3COMPLETEDEfficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
NCT00262106PHASE3COMPLETEDTrial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection
NCT00306787PHASE3COMPLETEDEfficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
NCT01281007PHASE3COMPLETEDEfficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes
NCT04979975PHASE2NOT_YET_RECRUITINGEvaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes
NCT00158483PHASE2COMPLETEDAnti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212)
NCT00158509PHASE2COMPLETEDRandomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding
NCT00405821PHASE2COMPLETEDAcyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda
NCT00486200PHASE2COMPLETEDA Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
NCT01658826PHASE2TERMINATEDSafety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
NCT01765114PHASE2TERMINATEDA Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes
NCT02837575PHASE2COMPLETEDSafety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
NCT03146403PHASE2TERMINATEDMaintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
NCT03595995PHASE2UNKNOWNA Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621
NCT04165122PHASE2COMPLETEDMonoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection
NCT04714060PHASE2UNKNOWNUB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals
NCT06033261PHASE1/PHASE2COMPLETEDA Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
NCT07330440PHASE1ENROLLING_BY_INVITATIONA Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
NCT00231049PHASE1COMPLETEDTrial Evaluating Safety, Tolerability and Immune Response of AG-707
NCT02852876PHASE1COMPLETEDStudy to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food
NCT04222985PHASE1TERMINATEDSafety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2
NCT00023582Not specifiedCOMPLETEDHIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru
NCT00495573Not specifiedCOMPLETEDHSV-2 Shedding Resolution After Acyclovir Treatment
NCT00808405Not specifiedCOMPLETEDGUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
NCT01112956Not specifiedCOMPLETEDSerologic Assays for the Diagnosis of Herpes Simplex Virus Type 2
NCT01132716Not specifiedCOMPLETEDBioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
VALACYCLOVIR434
ACYCLOVIR411
FAMCICLOVIR45
AMENAMEVIR42
MELATONIN41
PRITELIVIR31